E
Cassava Sciences, Inc.
SAVA
$2.74
$0.166.20%
E
Sell
2/7/2025Downgrade
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D- on 2/7/2025 due to a decline in the total return index and volatility index.
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D- on 2/7/2025 due to a decline in the total return index and volatility index.
D
Sell
1/23/2025Upgraded
Cassava Sciences, Inc. (SAVA) was upgraded to D- from E+ on 1/23/2025 due to an increase in the volatility index.
Cassava Sciences, Inc. (SAVA) was upgraded to D- from E+ on 1/23/2025 due to an increase in the volatility index.
E
Sell
12/20/2024Downgrade
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D- on 12/20/2024 due to a decline in the total return index and volatility index.
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D- on 12/20/2024 due to a decline in the total return index and volatility index.
D
Sell
12/4/2024Upgraded
Cassava Sciences, Inc. (SAVA) was upgraded to D- from E+ on 12/4/2024 due to an increase in the valuation index, total return index and solvency index.
Cassava Sciences, Inc. (SAVA) was upgraded to D- from E+ on 12/4/2024 due to an increase in the valuation index, total return index and solvency index.
E
Sell
3/6/2024Downgrade
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D- on 3/6/2024 due to a decline in the total return index, solvency index and volatility index.
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D- on 3/6/2024 due to a decline in the total return index, solvency index and volatility index.
D
Sell
2/14/2024Upgraded
Cassava Sciences, Inc. (SAVA) was upgraded to D- from E+ on 2/14/2024 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.6311 to -$0.6107, and EBIT increased 3.12% from -$28.78M to -$27.88M.
Cassava Sciences, Inc. (SAVA) was upgraded to D- from E+ on 2/14/2024 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.6311 to -$0.6107, and EBIT increased 3.12% from -$28.78M to -$27.88M.
E
Sell
11/7/2023Downgrade
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D- on 11/7/2023 due to a decline in the total return index, growth index and solvency index. Operating cash flow declined 50.31% from -$13.26M to -$19.92M, the quick ratio declined from 13.48 to 9.49, and EBIT declined 8.54% from -$26.51M to -$28.78M.
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D- on 11/7/2023 due to a decline in the total return index, growth index and solvency index. Operating cash flow declined 50.31% from -$13.26M to -$19.92M, the quick ratio declined from 13.48 to 9.49, and EBIT declined 8.54% from -$26.51M to -$28.78M.
D
Sell
7/7/2023Upgraded
Cassava Sciences, Inc. (SAVA) was upgraded to D- from E+ on 7/7/2023 due to an increase in the valuation index and total return index.
Cassava Sciences, Inc. (SAVA) was upgraded to D- from E+ on 7/7/2023 due to an increase in the valuation index and total return index.
E
Sell
6/20/2023Downgrade
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D- on 6/20/2023 due to a decline in the valuation index.
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D- on 6/20/2023 due to a decline in the valuation index.
D
Sell
6/2/2023Upgraded
Cassava Sciences, Inc. (SAVA) was upgraded to D- from E+ on 6/2/2023 due to an increase in the valuation index.
Cassava Sciences, Inc. (SAVA) was upgraded to D- from E+ on 6/2/2023 due to an increase in the valuation index.
E
Sell
5/12/2023Downgrade
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D- on 5/12/2023 due to a decline in the total return index, solvency index and valuation index. The quick ratio declined from 28.46 to 13.48.
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D- on 5/12/2023 due to a decline in the total return index, solvency index and valuation index. The quick ratio declined from 28.46 to 13.48.
D
Sell
3/14/2023Downgrade
Cassava Sciences, Inc. (SAVA) was downgraded to D- from D on 03/14/2023.
Cassava Sciences, Inc. (SAVA) was downgraded to D- from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Cassava Sciences, Inc. (SAVA) was upgraded to D from E+ on 02/09/2023.
Cassava Sciences, Inc. (SAVA) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index, solvency index and volatility index. The quick ratio declined from 22.61 to 21.02.
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index, solvency index and volatility index. The quick ratio declined from 22.61 to 21.02.
D
Sell
5/5/2022Upgraded
Cassava Sciences, Inc. (SAVA) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
Cassava Sciences, Inc. (SAVA) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
Cassava Sciences, Inc. (SAVA) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 38.18 to 18.62.
Cassava Sciences, Inc. (SAVA) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 38.18 to 18.62.
D
Sell
11/9/2021Upgraded
Cassava Sciences, Inc. (SAVA) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
Cassava Sciences, Inc. (SAVA) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
E
Sell
11/8/2021Downgrade
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D on 11/8/2021 due to a substantial decline in the growth index, valuation index and efficiency index. Operating cash flow declined 122.85% from -$2.31M to -$5.14M, EBIT declined 45.43% from -$3.53M to -$5.14M, and net income declined 45.35% from -$3.53M to -$5.13M.
Cassava Sciences, Inc. (SAVA) was downgraded to E+ from D on 11/8/2021 due to a substantial decline in the growth index, valuation index and efficiency index. Operating cash flow declined 122.85% from -$2.31M to -$5.14M, EBIT declined 45.43% from -$3.53M to -$5.14M, and net income declined 45.35% from -$3.53M to -$5.13M.
D
Sell
8/13/2019Upgraded
Cassava Sciences, Inc. (SAVA) was upgraded to D from D- on 8/13/2019 due to an increase in the growth index and efficiency index. Earnings per share increased from -$0.0792 to -$0.0617, net income increased 22.08% from -$1.36M to -$1.06M, and EBIT increased 20.54% from -$1.45M to -$1.15M.
Cassava Sciences, Inc. (SAVA) was upgraded to D from D- on 8/13/2019 due to an increase in the growth index and efficiency index. Earnings per share increased from -$0.0792 to -$0.0617, net income increased 22.08% from -$1.36M to -$1.06M, and EBIT increased 20.54% from -$1.45M to -$1.15M.
D
Sell
6/27/2019Downgrade
Cassava Sciences, Inc. (SAVA) was downgraded to D- from D on 6/27/2019 due to a decline in the volatility index and valuation index.
Cassava Sciences, Inc. (SAVA) was downgraded to D- from D on 6/27/2019 due to a decline in the volatility index and valuation index.
D
Sell
5/16/2019Upgraded
Cassava Sciences, Inc. (SAVA) was upgraded to D from D- on 5/16/2019 due to a large increase in the growth index, volatility index and total return index.
Cassava Sciences, Inc. (SAVA) was upgraded to D from D- on 5/16/2019 due to a large increase in the growth index, volatility index and total return index.
D
Sell
3/13/2017Upgraded
Pain Therapeutics, Inc. (PTIE) was upgraded to D- from E+ on 3/13/2017 due to an increase in the growth index and solvency index. The quick ratio increased from 10.04 to 28.14, EBIT increased 28.18% from -$3.54M to -$2.54M, and earnings per share increased from -$0.0769 to -$0.0597.
Pain Therapeutics, Inc. (PTIE) was upgraded to D- from E+ on 3/13/2017 due to an increase in the growth index and solvency index. The quick ratio increased from 10.04 to 28.14, EBIT increased 28.18% from -$3.54M to -$2.54M, and earnings per share increased from -$0.0769 to -$0.0597.
E
Sell
12/2/2016Downgrade
Pain Therapeutics, Inc. (PTIE) was downgraded to E+ from D- on 12/2/2016 due to a significant decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.066 to -$0.0769, and EBIT declined 16.33% from -$3.04M to -$3.54M.
Pain Therapeutics, Inc. (PTIE) was downgraded to E+ from D- on 12/2/2016 due to a significant decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.066 to -$0.0769, and EBIT declined 16.33% from -$3.04M to -$3.54M.
D
Sell
9/26/2016Downgrade
Pain Therapeutics Inc. (PTIE) was downgraded to D- from D on 9/26/2016 due to a decline in the efficiency index, valuation index and solvency index. Total capital declined 9.08% from $25.28M to $22.99M.
Pain Therapeutics Inc. (PTIE) was downgraded to D- from D on 9/26/2016 due to a decline in the efficiency index, valuation index and solvency index. Total capital declined 9.08% from $25.28M to $22.99M.
D
Sell
4/11/2016Upgraded
Pain Therapeutics Inc. (PTIE) was upgraded to D from D- on 4/11/2016 due to an increase in the volatility index and total return index.
Pain Therapeutics Inc. (PTIE) was upgraded to D from D- on 4/11/2016 due to an increase in the volatility index and total return index.
D
Sell
3/11/2016Downgrade
Pain Therapeutics Inc. (PTIE) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index, total return index and growth index. Operating cash flow declined 47.22% from -$2.41M to -$3.55M, earnings per share declined from -$0.0809 to -$0.0996, and EBIT declined 23.01% from -$3.69M to -$4.53M.
Pain Therapeutics Inc. (PTIE) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index, total return index and growth index. Operating cash flow declined 47.22% from -$2.41M to -$3.55M, earnings per share declined from -$0.0809 to -$0.0996, and EBIT declined 23.01% from -$3.69M to -$4.53M.
D
Sell
2/20/2015Downgrade
Pain Therapeutics Inc. (PTIE) was downgraded to D from C+ on 2/20/2015 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from -$0.0779 to -$0.0475, net income declined 38.99% from -$3.53M to -$2.16M, and EBIT declined 38.87% from -$3.55M to -$2.17M.
Pain Therapeutics Inc. (PTIE) was downgraded to D from C+ on 2/20/2015 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from -$0.0779 to -$0.0475, net income declined 38.99% from -$3.53M to -$2.16M, and EBIT declined 38.87% from -$3.55M to -$2.17M.
C
Hold
11/28/2014Downgrade
Pain Therapeutics Inc. (PTIE) was downgraded to C+ from B- on 11/28/2014 due to a decline in the total return index.
Pain Therapeutics Inc. (PTIE) was downgraded to C+ from B- on 11/28/2014 due to a decline in the total return index.
B
Buy
11/7/2014Upgraded
Pain Therapeutics Inc. (PTIE) was upgraded to B- from C on 11/7/2014 due to an increase in the valuation index, growth index and efficiency index. Net income increased 8.87% from -$3.25M to -$3.53M, EBIT increased 8.84% from -$3.26M to -$3.55M, and earnings per share increased from -$0.0717 to -$0.0779.
Pain Therapeutics Inc. (PTIE) was upgraded to B- from C on 11/7/2014 due to an increase in the valuation index, growth index and efficiency index. Net income increased 8.87% from -$3.25M to -$3.53M, EBIT increased 8.84% from -$3.26M to -$3.55M, and earnings per share increased from -$0.0717 to -$0.0779.
C
Hold
8/14/2014Downgrade
Pain Therapeutics Inc. (PTIE) was downgraded to C from C+ on 8/14/2014 due to a decline in the volatility index.
Pain Therapeutics Inc. (PTIE) was downgraded to C from C+ on 8/14/2014 due to a decline in the volatility index.
C
Hold
8/8/2014Downgrade
Pain Therapeutics Inc. (PTIE) was downgraded to C+ from B on 8/8/2014 due to a large decline in the solvency index, volatility index and growth index. The quick ratio declined from 29.11 to 25.78, earnings per share declined from -$0.0765 to -$0.0717, and EBIT declined 5.98% from -$3.46M to -$3.26M.
Pain Therapeutics Inc. (PTIE) was downgraded to C+ from B on 8/8/2014 due to a large decline in the solvency index, volatility index and growth index. The quick ratio declined from 29.11 to 25.78, earnings per share declined from -$0.0765 to -$0.0717, and EBIT declined 5.98% from -$3.46M to -$3.26M.
B
Buy
8/1/2014Downgrade
Pain Therapeutics Inc. (PTIE) was downgraded to B from B+ on 8/1/2014 due to a noticeable decline in the volatility index and total return index.
Pain Therapeutics Inc. (PTIE) was downgraded to B from B+ on 8/1/2014 due to a noticeable decline in the volatility index and total return index.
B
Buy
5/16/2014Downgrade
Pain Therapeutics Inc. (PTIE) was downgraded to B+ from A- on 5/16/2014 due to a major decline in the growth index, total return index and valuation index. Earnings per share declined from $0.7221 to -$0.0765, and EBIT declined 110.53% from $32.9M to -$3.46M.
Pain Therapeutics Inc. (PTIE) was downgraded to B+ from A- on 5/16/2014 due to a major decline in the growth index, total return index and valuation index. Earnings per share declined from $0.7221 to -$0.0765, and EBIT declined 110.53% from $32.9M to -$3.46M.
NASDAQ
03/12/2025 3:48PM Eastern
Quotes delayed
